The University of Southampton
University of Southampton Institutional Repository

Sex differences in the response of children with ADHD to once-daily formulations of Methylphenidate

Sex differences in the response of children with ADHD to once-daily formulations of Methylphenidate
Sex differences in the response of children with ADHD to once-daily formulations of Methylphenidate
Objectives: Studies of sex differences in methylphenidate response by children with attention-deficit/hyperactivity disorder have lacked methodological rigor and statistical power. This paper reports an examination of sex differences based on further analysis of data from a comparison of two once-daily methylphenidate formulations (the COMACS study), which addresses these shortcomings.
Method: Children (184: 48 females; mean [SD] age, 9.58 [1.83] years) entered a double-blind, crossover trial of Concerta, MetadateCD/Equasym XL, or placebo. Attention-deficit/hyperactivity disorder symptoms were recorded at seven time points across the school day on the seventh day of treatment, using a laboratory classroom setting.
Results: More females had comorbid anxiety disorder. Males and females did not differ with regard to other characteristics. Observed sex differences in pharmacodynamic symptom profiles persisted after controlling for placebo and time 0 hours attention-deficit/hyperactivity disorder scores and the presence of an anxiety disorder. Females had a statistically superior response at 1.5 hours post-dosing and an inferior response at the 12-hour time point relative to their male counterparts, no matter which methylphenidate formulation was being assessed.
Conclusions: Dose titration of once-daily formulations of methylphenidate should ideally be based on systematic evidence of response at different periods across the day. The responses of female patients may require additional assessments later in the day to determine the optimal dose.
1527-5418
701-710
Sonuga-Barke, E.J.S.
bc80bf95-6cf9-4c76-a09d-eaaf0b717635
Coghill, D.
a4b982d1-4788-41aa-90c5-b4a7f7dffad7
Markowitz, J.S.
fcb4b3a8-39c3-45be-b2b8-8f757ccea295
Swanson, J.M.
745c2c76-3510-4542-850d-4d084f748b2c
Vandenberghe, M.
6bebf94b-30a0-4963-9c21-adc9b02b9a5d
Hatch, S.
4b6224bb-6a4e-49b2-9703-0a84d5d12525
Sonuga-Barke, E.J.S.
bc80bf95-6cf9-4c76-a09d-eaaf0b717635
Coghill, D.
a4b982d1-4788-41aa-90c5-b4a7f7dffad7
Markowitz, J.S.
fcb4b3a8-39c3-45be-b2b8-8f757ccea295
Swanson, J.M.
745c2c76-3510-4542-850d-4d084f748b2c
Vandenberghe, M.
6bebf94b-30a0-4963-9c21-adc9b02b9a5d
Hatch, S.
4b6224bb-6a4e-49b2-9703-0a84d5d12525

Sonuga-Barke, E.J.S., Coghill, D., Markowitz, J.S., Swanson, J.M., Vandenberghe, M. and Hatch, S. (2007) Sex differences in the response of children with ADHD to once-daily formulations of Methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry, 46 (6), 701-710.

Record type: Article

Abstract

Objectives: Studies of sex differences in methylphenidate response by children with attention-deficit/hyperactivity disorder have lacked methodological rigor and statistical power. This paper reports an examination of sex differences based on further analysis of data from a comparison of two once-daily methylphenidate formulations (the COMACS study), which addresses these shortcomings.
Method: Children (184: 48 females; mean [SD] age, 9.58 [1.83] years) entered a double-blind, crossover trial of Concerta, MetadateCD/Equasym XL, or placebo. Attention-deficit/hyperactivity disorder symptoms were recorded at seven time points across the school day on the seventh day of treatment, using a laboratory classroom setting.
Results: More females had comorbid anxiety disorder. Males and females did not differ with regard to other characteristics. Observed sex differences in pharmacodynamic symptom profiles persisted after controlling for placebo and time 0 hours attention-deficit/hyperactivity disorder scores and the presence of an anxiety disorder. Females had a statistically superior response at 1.5 hours post-dosing and an inferior response at the 12-hour time point relative to their male counterparts, no matter which methylphenidate formulation was being assessed.
Conclusions: Dose titration of once-daily formulations of methylphenidate should ideally be based on systematic evidence of response at different periods across the day. The responses of female patients may require additional assessments later in the day to determine the optimal dose.

This record has no associated files available for download.

More information

Published date: 2007

Identifiers

Local EPrints ID: 48228
URI: http://eprints.soton.ac.uk/id/eprint/48228
ISSN: 1527-5418
PURE UUID: 609ae75c-7ada-4d55-a364-d5bb75356025

Catalogue record

Date deposited: 06 Sep 2007
Last modified: 08 Jan 2022 03:59

Export record

Contributors

Author: E.J.S. Sonuga-Barke
Author: D. Coghill
Author: J.S. Markowitz
Author: J.M. Swanson
Author: M. Vandenberghe
Author: S. Hatch

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×